Every 10-Q that Vistagen Therapeutics Inc (VTGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VTGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTGN filings page.
Vistagen Therapeutics, Inc. reported a net loss of $13.0 million for the quarter ended June 30, 2026, improving from a $15.1 million loss a year earlier. Revenue rose to $1.5 million from $0.2 million, driven by sublicense and collaboration activity. Operating expenses remained high at $14.8 million, largely for research and development of its pherine-based neuroscience pipeline.
Cash, cash equivalents and marketable securities totaled $31.7 million, down from $45.4 million at March 31, 2026, with $14.7 million used in operating activities during the quarter. The company disclosed substantial doubt about its ability to continue as a going concern within one year without additional financing and expects continuing losses. Nasdaq granted an extension until February 1, 2027 to regain compliance with the $1.00 minimum bid price requirement.
Vistagen advanced multiple clinical programs. For lead candidate fasedienol in social anxiety disorder, one Phase 3 trial (PALISADE-2) was previously positive, while others did not meet primary endpoints; post-hoc analyses showed nominal benefits in very severe patients. The company believes it now meets ICH E1 exposure recommendations and plans FDA discussions on a potential registrational path. Refisolone and itruvone also progressed, with refisolone cleared to proceed in U.S. Phase 2 for menopausal hot flashes.
Vistagen Therapeutics, Inc. reported a larger quarterly loss as it continues funding late-stage development of its intranasal pherine neuroscience pipeline. For the quarter ended December 31, 2025, revenue was $0.3 million, while research and development and general and administrative expenses rose to $14.2 million and $5.6 million, respectively, leading to a net loss of $18.9 million.
For the nine-month period, revenue reached $0.8 million and net loss widened to $53.4 million as the company advanced its Phase 3 PALISADE program for fasedienol in social anxiety disorder and progressed other pherine candidates. Cash, cash equivalents and marketable securities totaled $61.8 million, but management concluded there is substantial doubt about Vistagen’s ability to continue as a going concern beyond twelve months without additional financing. The company also received a Nasdaq notice for not meeting the $1.00 minimum bid price requirement.
Vistagen Therapeutics reported Q2 FY2026 results for the quarter ended September 30, 2025. Revenue was $258 thousand, while operating expenses rose to $20.3 million, driven by higher R&D ($15.9 million) and steady G&A ($4.4 million). The company posted a net loss of $19.4 million (basic and diluted net loss per share of $0.54).
Liquidity remained solid with cash, cash equivalents and marketable securities of $77.2 million as of September 30, 2025. Management concluded that “substantial doubt” exists about the company’s ability to continue as a going concern beyond twelve months from the financial statement issuance date.
Vistagen strengthened its balance sheet via its at-the-market program, selling 9,608,772 shares in the quarter for net proceeds of $27.9 million. Shares issued were 38,895,568 at September 30, 2025; as of November 12, 2025, 39,495,451 shares were outstanding. Deferred revenue totaled $2.5 million, primarily related to its AffaMed collaboration and Fuji Pharma negotiation agreement.